- Invitae, a next-gen healthcare/biotech company, has seen its stock getting hammered due to strong worries about a looming bankruptcy due to reckless cash burn.
- However, in the last few quarters, the company has started to shift from growth-at-all-costs to focusing on reducing the cash burn, with a $100M annualized reduction in Q1 alone.
- Invitae continues to target strong long-term growth and to become cash flow positive by 2025.
- At the current valuation, the risk/reward is shifting significantly such that even a small bet could lead to compelling returns.
For further details see:
Invitae: Coming Out Of The Cash Burn